Dermapharm Holding SE (DMPHF)

42.68 0.00 (0.00%) At close: 04:05PM EDT

Dermapharm Holding SE

Lil-Dagover-Ring 7
Grünwald 82031
Germany
49 89 6 41 86 0
https://ir.dermapharm.de

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 3,497

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Hans-Georg Feldmeier	CEO & Chairman of the Management Board	1.13M	N/A	N/A
Mr. Christof Dreibholz	CFO, Chief Compliance Officer & Member of Management Board	660.13k	N/A	1968
Dr. Andreas Eberhorn	Chief Marketing Officer & Member of Management Board	654.78k	N/A	1976
Ms. Britta Hamberger	Head of Investor Relations & Corporate Communications	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany and internationally. It operates through three segments: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. The company develops, manufactures, licenses, markets, and sells branded generics, over-the-counter drugs, non-prescription healthcare products, herbal extracts, and other pharmaceutical products. It offers healthcare products in the areas of vitamins, minerals, food supplements, dermatology, allergology, pain and inflammation treatment, cardiovascular support, gynecology, and urology. The company also provides medical devices under the bite away and Herpotherm names. Further, it imports originator pharmaceuticals under the axicorp brand; and offers herbal extracts and natural active ingredients for phytopharmaceuticals, nutraceuticals, and cosmetics. The company was founded in 1991 and is based in Grünwald, Germany. Dermapharm Holding SE operates as a subsidiary of Themis Beteiligungs-AG.

Corporate governance

Dermapharm Holding SE’s ISS governance QualityScore as of 1 April 2024 is 10. The pillar scores are Audit: 7; Board: 10; Shareholder rights: 6; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.